News

The study evaluated two concentrations of bepotastine, each dosed once daily and twice daily. The primary endpoints of the study were the assessment of efficacy for bepotastine in

The initial phase II study will test single and repeated doses of BIIB014 in patients with late-stage Parkinson’s disease, in addition to the usual L-dopa therapy. The second

The drug is a bioreductively-activated, hypoxia-selective small molecule that acts primarily in hypoxic regions of tumors, wherein tirapazamine radicals cause double-stranded DNA breaks. It was originally identified as

A compulsory license allows Brazil, under World Trade Organization (WTO) rules, to buy or manufacture generic versions of the drug. Thailand recently earned itself a place on the

Specifically, Abbott has applied to market Humira (adalimumab) as a treatment for juvenile rheumatoid arthritis (JRA) in the US and juvenile idiopathic arthritis (JIA) in the European Union.

Alba’s study, the first phase IIa trial in celiac disease (CD) and the first to assess dosing requirements for AT-1001 in CD, was designed to evaluate the safety,

The patient died from fulminant hepatitis, also known as acute liver failure, according to the company. Astellas is jointly developing the compound with US biotech company FibroGen, which

New data from a randomized, double-blind study showed that a combination of Copaxone with the oral antibiotic minocycline reduced T1 Gadolinium enhancing lesions of the brain by 63%

The drug discovery programs currently being managed in Waltham will be moved to Munich, where the company has its headquarters, while GPC will continue to build its clinical